No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 29.4x · 10Y median 30.1x · 48th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-03-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-03-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-03-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-03-17.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-03-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-03-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:32:01.490Z. Latest historical point 2026-03-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Monte Rosa Therapeutics, Inc. (GLUE) stock was $10.00 as of Oct 6, 2026, 10:30 AM EDT, down 2.63% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +32.5% · 3-year avg +31.2%/yr · 5-year avg -12.3%/yr
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines.
Biotechnology · Boston, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.24
Revenue Est.
$31.47M
Last Quarter Results
EPS
$-0.43
vs Estimate
$-0.37
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GLUE | $844.79M | $10.00 | -2.63% | +32.51% | -12.32% | N/A | N/A |
| 2BBNX | $836.58M | $18.59 | -1.87% | -14.80% | N/A | N/A | vs GLUE |
| 3CRVS | $864.45M | $10.28 | -4.28% | +49.09% | +17.88% | -4.26% | vs GLUE |
| 4ALMS | $823.29M | $6.67 | -2.49% | +69.72% | N/A | N/A | vs GLUE |
| 5JBIO | $820.39M | $13.48 | -4.19% | +58.45% | -52.65% | N/A | vs GLUE |
| 6APMD | $810.40M | $20.35 | -6.44% | N/A | N/A | N/A | vs GLUE |
forward FY estimate
N/A
$9.00M
vs Estimate
$12.91M
Consensus Rating
Based on 7 analysts
Average Price Target
$28.00
+180.0% upside
Low
$25.00
Current
$10.00
High
$37.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.08 | $-0.24 | $0.24 | 6 |
| Quarter ending Dec 2026 | $-0.73 | $-0.37 | $0.56 | 6 |
| Quarter ending Mar 2027 | $-2.19 | $-0.57 | $0.05 | 2 |
| Quarter ending Jun 2027 | $-2.32 | $-0.61 | $0.06 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.18 | $-1.48 | $-0.49 | 6 |
| FY 2027 | $-2.80 | $-1.97 | $0.30 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $6.25M | $31.47M | $46.38M | 6 |
| Quarter ending Dec 2026 | $3.65M | $23.16M | $73.48M | 6 |
| Quarter ending Mar 2027 | $739628.00 | $4.70M | $14.91M | 3 |
| Quarter ending Jun 2027 | $739628.00 | $4.70M | $14.91M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $22.63M | $67.80M | $138.45M | 6 |
| FY 2027 | $17.18M | $53.93M | $158.65M | 6 |
